Search research articles
Contact Us
Filters
Showing results (171-180 of 175) with videos related to
Page
of 18
Sort By:
You have reached the last page of results.
This site can display upto 175 results.
Cancers
|
September 14, 2024
Initial Trans-Arterial Chemo-Embolisation (TACE) Is Associated with Similar Survival Outcomes as Compared to Upfront Percutaneous Ablation Allowing for Follow-Up Treatment in Those with Single Hepatocellular Carcinoma (HCC) ≤ 3 cm: Results of a Real-World Propensity-Matched Multi-Centre Australian Cohort Study
Jonathan Abdelmalak, Simone I Strasser, Natalie L Ngu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 5, 2020
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics
Timothy Papaluca, Stuart K Roberts, Simone I Strasser, et al.
Gastroenterology
|
April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Ira M Jacobson, Eric Lawitz, Edward J Gane, et al.
Gastroenterology
|
April 20, 2010
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
Alexander J Thompson, Andrew J Muir, Mark S Sulkowski, et al.
Hepatology Communications
|
April 1, 2026
The diagnosis and management of portal hypertension in cirrhosis: The Gastroenterological Society of Australia consensus
Avik Majumdar, Jacinta Holmes, Stuart K Roberts, et al.
Page
of 18
Search research articles
Search
Showing results (171-180 of 175) with videos related to
Sort By:
Page
of 18
You have reached the last page of results.
This site can display upto 175 results.
Cancers
|
September 14, 2024
Initial Trans-Arterial Chemo-Embolisation (TACE) Is Associated with Similar Survival Outcomes as Compared to Upfront Percutaneous Ablation Allowing for Follow-Up Treatment in Those with Single Hepatocellular Carcinoma (HCC) ≤ 3 cm: Results of a Real-World Propensity-Matched Multi-Centre Australian Cohort Study
Jonathan Abdelmalak, Simone I Strasser, Natalie L Ngu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 5, 2020
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics
Timothy Papaluca, Stuart K Roberts, Simone I Strasser, et al.
Gastroenterology
|
April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Ira M Jacobson, Eric Lawitz, Edward J Gane, et al.
Gastroenterology
|
April 20, 2010
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
Alexander J Thompson, Andrew J Muir, Mark S Sulkowski, et al.
Hepatology Communications
|
April 1, 2026
The diagnosis and management of portal hypertension in cirrhosis: The Gastroenterological Society of Australia consensus
Avik Majumdar, Jacinta Holmes, Stuart K Roberts, et al.
Page
of 18